FAP nuclear theranostics: Calais looks at the current state of scientific and industry interest in advancing imaging and therapy with fibroblast activation proteins targeting cancer-associated fibroblasts, a major constituent of tumor stroma.
Page 163
Spatial-temporal ordering of amyloid: Fantoni and colleagues summarize current research in detection of regional amyloid deposition patterns and the potential for staging amyloid pathology, including expanding applications of PET imaging.
Page 166
Steroid hormone receptor imaging: Kumar and colleagues highlight recent achievements in preclinical and clinical imaging of estrogen and progesterone receptors in breast cancer.
Page 172
Mutation patterns in radioiodine refractoriness: Liu and colleagues investigate the role of BRAF V600E and TERT promoter mutations, particularly in tandem, in loss of radioactive iodine avidity in recurrent papillary thyroid cancer.
Page 177
18F-DCFPyL versus Na18F: Rowe and colleagues undertake a head-to-head comparison of prostate-specific membrane antigen–targeted 18F-DCFPyL PET and Na18F PET to determine which is more sensitive for detection of lesions suggestive of bone metastases in prostate cancer.
Page 183
Reducing 68Ga PET/CT dose? Rauscher and colleagues explore the definition of a clinically useful lower limit of injected dose for 68Ga–prostate-specific membrane antigen–11 PET/CT imaging of prostate cancer.
Page 189
68Ga-PSMA-11 PET/MRI: Kranzbühler and colleagues focus on patients with biochemical recurrence of prostate cancer and prostate-specific antigen values ≤0.5 ng/mL to assess the detection rate for 68Ga-PSMA-11 PET/MRI.
Page 194
18F-JK-PSMA-7 PET/CT: Dietlein and colleagues assess the clinical utility of 18F-JK–prostate-specific membrane antigen–7 for PET/CT imaging of patients with prostate cancer and compare findings with those from 68Ga-PSMA-11 imaging.
Page 202
Advanced reconstruction for PSMA PET: Jansen and colleagues explore the impact of advanced PET image reconstruction methods on biochemically recurrent prostate cancer localization and interobserver agreement with 18F-DCFPyL PET/CT scans in patients with low prostate-specific antigen values.
Page 210
Tumor-to-blood ratio in NETs: Ilan and colleagues evaluate the tumor-to-blood ratio as an alternative tool for semiquantitative assessment of 68Ga-DOTATOC and 68Ga-DOTATATE tumor uptake and for therapy monitoring in patients with neuroendocrine tumors.
Page 217
177Lu-DOTATATE in NETS: Hope and members of the North American Neuroendocrine Tumor Society and SNMMI present a consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy in neuroendocrine tumors.
Page 222
Metal-ion labeled DOTATATE imaging: Andersen and colleagues compare 68Ga-DOTATATE, 64Cu-DOTATATE, and 55Co-DOTATATE PET/CT in mice to determine whether the 55Co label conveys advantages for imaging at delayed time points.
Page 228
Cyanine-spacer–based PSMA hybrid tracers: Hensbergen and colleagues describe development of a 99mTc-labeled prostate-specific membrane antigen–targeted tracer incorporating a fluorescent dye for radioguided surgery.
Page 234
TRT radiopharmaceuticals for mGluR1: Xie and colleagues describe 2 new radiopharmaceuticals, 131I-IITM and 211At-AITM, targeting the ectopic metabotropic glutamate receptor 1 in melanomas for radionuclide therapy studies.
Page 242
PET after cardiac transplantation: Miller and colleagues compare the diagnostic and prognostic utility of stress myocardial blood flow and myocardial flow reserve quantitation by PET in cardiac allograft vasculopathy after cardiac transplantation.
Page 249
Recovered mGluR5 in alcohol dependence: Ceccarini and colleagues research whether decreased cerebral metabotropic glutamate receptor 5 availability in alcohol-dependent patients normalizes during abstinence and whether initial 18F-FPEB mGluR5 imaging parameters can predict individual relapse.
Page 256
Tau PET in syntactic network disease: Pascual and colleagues study tau propagation patterns in the left hemispheric syntactic network in patients with nonfluent primary progressive aphasia.
Page 263
68Ga-RGD PET/CT and angiogenesis: Lobeek and colleagues detail the results of a clinical feasibility study designed to demonstrate that 68Ga-labeled arginine-glycine-aspartate tripeptide sequence PET/CT can be used to quantitatively assess angiogenesis in peripheral arteriovenous malformations.
Page 270
18F-FDG PET/MRI and CMRGlc mapping: Shiyam Sundar and colleagues describe a fully automated processing pipeline to support noninvasive absolute quantification of the cerebral metabolic rate for glucose in a clinical setting.
Page 276
Total-body parametric PET/CT imaging: Zhang and colleagues demonstrate the capability of total-body parametric imaging and quantify improvements in image quality and kinetic parameter estimation by direct and kernel reconstruction of uEXPLORER data.
Page 285
High-throughput small-animal PET/CT: Greenwood and colleagues report on development of a device to simultaneously image up to 4 mice, thereby reducing costs and maximizing radiotracer efficiency when compared with scans performed on a single mouse bed.
Page 292
Denoising nuclear medicine images: Minarik and colleagues investigate whether noise can be removed in whole-body bone scans using convolutional neural networks trained with sets of noisy and noiseless images obtained by Monte Carlo simulation.
Page 298
- © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.